Analysis of age influence on oncological results and toxicity of BCG immunotherapy in non-muscle invasive bladder cancer
暂无分享,去创建一个
F. Pisano | Ó. Rodríguez Faba | W. Krajewski | S. Poletajew | A. Tukiendorf | R. Zdrojowy | A. Breda | J. Palou | A. Kołodziej
[1] G. Stallone,et al. The impact of age on intravesical instillation of Bacille Calmette–Guerin treatment in patients with high-grade T1 bladder cancer , 2019, Medicine.
[2] Maximilian Burger,et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. , 2017, European urology.
[3] T. D. de Reijke,et al. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911. , 2014, European urology.
[4] M. Babjuk,et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. , 2013, European urology.
[5] A. Finelli,et al. Diminished efficacy of Bacille Calmette-Guérin among elderly patients with nonmuscle invasive bladder cancer. , 2011, Urology.
[6] E. Kikuchi,et al. Could patient age influence tumor recurrence rate in non-muscle-invasive bladder cancer patients treated with BCG immunotherapy? , 2011, Japanese journal of clinical oncology.
[7] L. Martínez-Piñeiro,et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. , 2009, The Journal of urology.
[8] A. Sjölander. Propensity scores and M‐structures , 2009, Statistics in medicine.
[9] W. Savino,et al. Can the Immune System Still Be Efficient in the Elderly? An Immunological and Immunoendocrine Therapeutic Perspective , 2008, Neuroimmunomodulation.
[10] M. Terris,et al. Effect of advanced age on the development of complications from intravesical bacillus Calmette-Guérin therapy. , 2008, Urologic oncology.
[11] H. Herr. Age and outcome of superficial bladder cancer treated with bacille Calmette-Guérin therapy. , 2007, Urology.
[12] Y. Uekado,et al. Intravesical instillation therapy with bacillus Calmette‐Guérin for superficial bladder cancer: Study of the mechanism of bacillus Calmette‐Guérin immunotherapy , 2007, International journal of urology : official journal of the Japanese Urological Association.
[13] Brian J. Smith,et al. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. , 2006, The Journal of urology.
[14] J Alfred Witjes,et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. , 2006, European urology.
[15] L. Seroude,et al. Immunity and aging: the enemy within? , 2004, Aging cell.